Clinical Trial Update: A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C [Phase 1]

View source ↗

Summary

This document reports results from a Phase 1 study evaluating MP-424 in combination with peginterferon alfa-2b and ribavirin for hepatitis C, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MP-424
• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2013-01-18